Iridium [IRMD] vs Abbott Laboratories [ABT] Detailed Stock Comparison
Iridium
NASDAQ
Loading...
Abbott Laboratories
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Iridium wins in 6 metrics, Abbott Laboratories wins in 14 metrics, with 0 ties. Abbott Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Iridium | Abbott Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 44.39 | 16.78 | Abbott Laboratories |
| Price-to-Book Ratio | 9.64 | 4.60 | Abbott Laboratories |
| Debt-to-Equity Ratio | 0.00 | 26.50 | Iridium |
| PEG Ratio | 2.89 | 0.46 | Abbott Laboratories |
| EV/EBITDA | 34.87 | 20.89 | Abbott Laboratories |
| Profit Margin (TTM) | 26.61% | 32.43% | Abbott Laboratories |
| Operating Margin (TTM) | 33.26% | 19.73% | Iridium |
| EBITDA Margin (TTM) | 33.26% | 19.73% | Iridium |
| Return on Equity | 23.75% | 30.93% | Abbott Laboratories |
| Return on Assets (TTM) | 15.15% | 6.62% | Iridium |
| Free Cash Flow (TTM) | $16.81M | $6.35B | Abbott Laboratories |
| Dividend Yield | 1.15% | 1.28% | Abbott Laboratories |
| 1-Year Return | 50.85% | 18.36% | Iridium |
| Price-to-Sales Ratio (TTM) | 11.71 | 5.40 | Abbott Laboratories |
| Enterprise Value | $857.88M | $239.20B | Abbott Laboratories |
| EV/Revenue Ratio | 11.05 | 5.55 | Abbott Laboratories |
| Gross Profit Margin (TTM) | 78.17% | 56.44% | Iridium |
| Revenue per Share (TTM) | $6 | $25 | Abbott Laboratories |
| Earnings per Share (Diluted) | $1.61 | $7.97 | Abbott Laboratories |
| Beta (Stock Volatility) | 1.03 | 0.69 | Abbott Laboratories |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Iridium vs Abbott Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Iridium | 2.28% | -2.54% | 3.24% | 23.83% | 39.06% | 31.74% |
| Abbott Laboratories | 0.30% | 1.45% | 3.30% | 1.63% | 6.55% | 18.63% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Iridium | 50.85% | 133.41% | 244.01% | 178.28% | 722.50% | 722.50% |
| Abbott Laboratories | 18.36% | 33.66% | 30.08% | 229.34% | 440.01% | 534.17% |
News Based Sentiment: Iridium vs Abbott Laboratories
Iridium
News based Sentiment: MIXED
September presented a mixed bag for Iridium, with an earnings miss and a significant competitive threat from SpaceX offset by new contracts, a dividend increase, and continued institutional investment. The emergence of SpaceX as a competitor is a major development that warrants close attention, making this a significant month for the company's investment story.
Abbott Laboratories
News based Sentiment: MIXED
September was a month of contrasts for Abbott, with positive Q2 earnings and continued innovation initiatives tempered by a lowered revenue forecast due to challenges in China. This creates a mixed investment picture, requiring investors to carefully weigh the company's strengths and weaknesses.
Performance & Financial Health Analysis: Iridium vs Abbott Laboratories
| Metric | IRMD | ABT |
|---|---|---|
| Market Information | ||
| Market Cap | $908.97M | $232.75B |
| Market Cap Category | Small cap | Mega cap |
| 10 Day Avg. Volume | 35,245 | 5,176,450 |
| 90 Day Avg. Volume | 46,555 | 5,323,787 |
| Last Close | $72.38 | $134.57 |
| 52 Week Range | $46.86 - $74.43 | $110.86 - $141.23 |
| % from 52W High | -2.76% | -4.72% |
| All-Time High | $74.43 (Sep 11, 2025) | $142.60 (Dec 27, 2021) |
| % from All-Time High | -2.75% | -5.63% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.14% | 0.07% |
| Quarterly Earnings Growth | 0.18% | 0.37% |
| Financial Health | ||
| Profit Margin (TTM) | 0.27% | 0.32% |
| Operating Margin (TTM) | 0.33% | 0.20% |
| Return on Equity (TTM) | 0.24% | 0.31% |
| Debt to Equity (MRQ) | 0.00 | 26.50 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $7.41 | $29.05 |
| Cash per Share (MRQ) | $4.17 | $4.18 |
| Operating Cash Flow (TTM) | $27.14M | $9.04B |
| Levered Free Cash Flow (TTM) | $7.10M | $5.92B |
| Dividends | ||
| Last 12-Month Dividend Yield | 1.15% | 1.28% |
| Last 12-Month Dividend | $0.81 | $1.69 |
Valuation & Enterprise Metrics Analysis: Iridium vs Abbott Laboratories
| Metric | IRMD | ABT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 44.39 | 16.78 |
| Forward P/E | 40.83 | 25.92 |
| PEG Ratio | 2.89 | 0.46 |
| Price to Sales (TTM) | 11.71 | 5.40 |
| Price to Book (MRQ) | 9.64 | 4.60 |
| Market Capitalization | ||
| Market Capitalization | $908.97M | $232.75B |
| Enterprise Value | $857.88M | $239.20B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 11.05 | 5.55 |
| Enterprise to EBITDA | 34.87 | 20.89 |
| Risk & Other Metrics | ||
| Beta | 1.03 | 0.69 |
| Book Value per Share (MRQ) | $7.41 | $29.05 |
Financial Statements Comparison: Iridium vs Abbott Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | IRMD | ABT |
|---|---|---|
| Revenue/Sales | $20.41M | $10.36B |
| Cost of Goods Sold | $4.45M | $4.47B |
| Gross Profit | $15.95M | $5.89B |
| Research & Development | $877,362 | $716.00M |
| Operating Income (EBIT) | $6.79M | $1.69B |
| EBITDA | $7.00M | $2.66B |
| Pre-Tax Income | $7.33M | $1.78B |
| Income Tax | $1.55M | $453.00M |
| Net Income (Profit) | $5.77M | $1.33B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | IRMD | ABT |
|---|---|---|
| Cash & Equivalents | $50.33M | $6.53B |
| Total Current Assets | $75.14M | $23.15B |
| Total Current Liabilities | $8.47M | $13.00B |
| Long-Term Debt | $0 | $12.74B |
| Total Shareholders Equity | $90.05M | $49.06B |
| Retained Earnings | $59.32M | $47.72B |
| Property, Plant & Equipment | $59,221 | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | IRMD | ABT |
|---|---|---|
| Operating Cash Flow | $4.67M | $1.42B |
| Capital Expenditures | $-3.70M | $-484.00M |
| Free Cash Flow | $374,792 | $933.00M |
| Debt Repayment | N/A | $-1.00B |
| Common Stock Repurchase | N/A | $-280.00M |
Short Interest & Institutional Ownership Analysis
| Metric | IRMD | ABT |
|---|---|---|
| Shares Short | 151,794 | 17.75M |
| Short Ratio | 2.60 | 3.27 |
| Short % of Float | 0.02% | 0.01% |
| Average Daily Volume (10 Day) | 35,245 | 5,176,450 |
| Average Daily Volume (90 Day) | 46,555 | 5,323,787 |
| Shares Outstanding | 12.71M | 1.73B |
| Float Shares | 7.17M | 1.73B |
| % Held by Insiders | 0.37% | 0.01% |
| % Held by Institutions | 0.59% | 0.81% |
Dividend Analysis & Yield Comparison: Iridium vs Abbott Laboratories
| Metric | IRMD | ABT |
|---|---|---|
| Last 12-Month Dividend | $0.81 | $1.69 |
| Last 12-Month Dividend Yield | 1.15% | 1.28% |
| 3-Year Avg Annual Dividend | $0.88 | $1.92 |
| 3-Year Avg Dividend Yield | 0.75% | 0.49% |
| 3-Year Total Dividends | $2.64 | $5.77 |
| Ex-Dividend Date | Aug 18, 2025 | Jan 15, 2025 |